Quick Takeaways
- EBS - Emergent BioSolutions Inc. has 27 insiders with reported activity on this page.
- Net insider value flow over the last year: -$1,574,401.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 27 Insiders of Emergent BioSolutions Inc.
- Symbol
- EBS on NYSE
- Location
- Gaithersburg, MD
What Changed
- Buy value: ; sell value: $1,574,400.
- Net share flow: -167,644.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$1,574,401.
Buys
$0
Shares: 0
Insiders: 0
Sells
$1,574,401
Shares: 167,644
Insiders: 7
Net
-$1,574,401
Shares: -167,644
Insiders: -7
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 65,925 | $0 | $552,000 | -$552,000 |
| 3-6 | 0 | 21,984 | $0 | $263,077 | -$263,077 |
| 6-9 | 0 | 56,961 | $0 | $579,223 | -$579,223 |
| 9-12 | 0 | 22,774 | $0 | $180,101 | -$180,101 |
Emergent BioSolutions Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Joseph C. Papa | President and CEO, Director | $4,093,169 | Median | 29 Apr 2026 | ||
| Richard S. Lindahl | EVP, Chief Financial Officer | $3,137,790 | Median | 29 Apr 2026 | ||
| Fuad El-Hibri | Director | $2,444,997 | Mixed | 03 Dec 2021 | ||
| Coleen Glessner | EVP, Quality & Ethics, and CPL | $1,695,017 | -$306,080 | -15% | Median | 29 Apr 2026 |
| William Hartzel | SVP, Bioservices | $1,554,581 | Median | 29 Apr 2026 | ||
| Jennifer Lynne Fox | EVP, Ext Aff, GC, Corp Sec | $1,515,286 | Mixed | 11 Jul 2024 | ||
| Simon C. Lowry | Svp, R&D, Cmo | $1,476,686 | Median | 29 Apr 2026 | ||
| Jessica Perl | SVP, General Counsel, Corp Sec | $1,371,873 | Median | 29 Apr 2026 | ||
| Paul Anthony Williams | SVP, Products Business | $1,351,173 | -$33,760 | -2.4% | Median | 29 Apr 2026 |
| Neal Franklin Fowler | Director | $1,335,030 | Median | 30 Apr 2026 | ||
| Zsolt Harsanyi | Chairman, Director | $1,237,330 | Median | 30 Apr 2026 | ||
| Donald W. DeGolyer | Director | $1,162,300 | -$385,447 | -25% | Filing P/S | 30 Apr 2026 |
| Ronald Richard | Director | $1,027,216 | -$263,077 | -20% | Median | 30 Apr 2026 |
| Marvin L. White | Director | $944,863 | Median | 30 Apr 2026 | ||
| Robert Kramer | President and CEO, Director | $921,027 | Mixed | 09 Jun 2023 | ||
| Sujata Tyagi Dayal | Director | $899,033 | -$201,130 | -18% | Filing P/S | 30 Apr 2026 |
| Keith Katkin | Director | $797,314 | -$177,600 | -18% | Filing P/S | 30 Apr 2026 |
| Kathryn C. Zoon | Director | $717,070 | -$207,306 | -22% | Filing P/S | 30 Apr 2026 |
| Louis W. Sullivan | Director | $610,640 | Mixed | 30 Apr 2025 | ||
| Adam Havey | EVP, Business Operations | $317,404 | Mixed | 09 Jun 2023 | ||
| John D. Fowler Jr. | Director | $251,905 | Median | 30 Apr 2026 | ||
| Atul Saran | EVP, Chief Strat & Dev Officer | $157,694 | Mixed | 28 Feb 2023 | ||
| Katherine Strei | EVP, Chief HR Officer | $114,340 | Mixed | 28 Feb 2023 | ||
| Jerome M. Hauer | Director | $104,665 | Mixed | 25 May 2023 | ||
| George A. Joulwan | Director | $73,244 | Mixed | 26 May 2022 | ||
| Karen L. Smith | EVP, Chief Medical Officer | $21,636 | Mixed | 07 May 2021 | ||
| H. Haywood Miller III | Interim CEO | Mixed | 24 Jun 2023 |
Top shareholders of Emergent BioSolutions Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
|
Company |
7.3%
from 13D/G
|
4,254,397
|
$52,584,347 | — | 31 Dec 2025 | |
| OAK HILL ADVISORS LP |
13F
|
Company |
7%
|
3,613,338
|
$44,660,858 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
6.9%
|
3,553,999
|
$43,927,428 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13D/G
13F
|
STATE STREET CORPORATION · Company |
5.1%
|
2,696,375
|
$33,408,086 | $0 | 31 Dec 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
4.7%
|
2,439,439
|
$30,151,466 | — | 31 Dec 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
13D/G
|
Company |
5.3%
from 13D/G
|
2,252,605
|
$27,840,949 | — | 31 Dec 2025 | |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
|
Vanguard Capital Management |
5%
|
2,605,090
|
$21,622,247 | $0 | 31 Mar 2026 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
3.1%
|
1,618,903
|
$20,009,641 | — | 31 Dec 2025 | |
| PALISADE CAPITAL MANAGEMENT, LP |
13F
|
Company |
2.4%
|
1,265,766
|
$15,644,863 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.4%
|
1,250,010
|
$15,453,820 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
2.2%
|
1,157,696
|
$14,309,141 | — | 31 Dec 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
2.1%
|
1,110,682
|
$13,723,000 | — | 31 Dec 2025 | |
| Jain Global LLC |
13F
|
Company |
1.8%
|
942,691
|
$11,651,661 | — | 31 Dec 2025 | |
| LSV ASSET MANAGEMENT |
13F
|
Company |
1.7%
|
901,000
|
$11,136,000 | — | 31 Dec 2025 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
1.5%
|
777,999
|
$9,616,068 | — | 31 Dec 2025 | |
| PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. |
13F
|
Company |
1.5%
|
772,771
|
$9,551,450 | — | 31 Dec 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
1.4%
|
743,455
|
$9,189,104 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.4%
|
740,100
|
$9,147,636 | — | 31 Dec 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
1.4%
|
723,217
|
$8,938,962 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
1.1%
|
580,622
|
$7,176,487 | — | 31 Dec 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
1.1%
|
577,147
|
$7,133,537 | — | 31 Dec 2025 | |
| NEW YORK STATE COMMON RETIREMENT FUND |
13F
|
Company |
1%
|
522,004
|
$6,451,969 | — | 31 Dec 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.92%
|
478,029
|
$5,908,438 | — | 31 Dec 2025 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.84%
|
434,774
|
$5,373,807 | — | 31 Dec 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.77%
|
395,457
|
$4,887,849 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.73%
|
377,712
|
$4,668,520 | — | 31 Dec 2025 | |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC |
13F
|
Company |
0.72%
|
373,902
|
$4,621,429 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.67%
|
347,805
|
$4,298,870 | — | 31 Dec 2025 | |
| Joseph C. Papa |
3/4/5
|
President and CEO, Director |
—
mixed-class rows
|
3,810,347
mixed-class rows
|
$4,093,169 | — | 29 Apr 2026 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.6%
|
311,784
|
$3,853,000 | — | 31 Dec 2025 | |
| Values First Advisors, Inc. |
13F
|
Company |
0.59%
|
305,046
|
$3,770,373 | — | 31 Dec 2025 | |
| Trexquant Investment LP |
13F
|
Company |
0.58%
|
301,689
|
$3,728,876 | — | 31 Dec 2025 | |
| Allianz Asset Management GmbH |
13F
|
Company |
0.56%
|
290,701
|
$3,593,064 | — | 31 Dec 2025 | |
| Russell Investments Group, Ltd. |
13F
|
Company |
0.52%
|
269,965
|
$3,336,765 | — | 31 Dec 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.5%
|
258,500
|
$3,195,060 | — | 31 Dec 2025 | |
| Richard S. Lindahl |
3/4/5
|
EVP, Chief Financial Officer |
—
mixed-class rows
|
1,419,883
mixed-class rows
|
$3,137,790 | — | 29 Apr 2026 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.47%
|
244,512
|
$3,022,163 | — | 31 Dec 2025 | |
| GLOBEFLEX CAPITAL L P |
13F
|
Company |
0.47%
|
241,298
|
$2,982,443 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.46%
|
237,674
|
$2,937,651 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.45%
|
232,019
|
$2,867,755 | — | 31 Dec 2025 | |
| Morse Asset Management, Inc |
13F
|
Company |
0.44%
|
229,308
|
$2,834,247 | — | 31 Dec 2025 | |
| Cetera Investment Advisers |
13F
|
Company |
0.42%
|
219,483
|
$2,712,810 | — | 31 Dec 2025 | |
| TRUIST FINANCIAL CORP |
13F
|
Company |
0.42%
|
219,452
|
$2,712,431 | — | 31 Dec 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.4%
|
206,002
|
$2,546,185 | — | 31 Dec 2025 | |
| Fuad El-Hibri |
3/4/5
|
Director |
—
class O/S missing
|
1,343,405
|
$2,444,997 | — | 03 Dec 2021 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.35%
|
181,744
|
$2,246,356 | — | 31 Dec 2025 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.34%
|
178,295
|
$2,203,726 | — | 31 Dec 2025 | |
| WOLVERINE ASSET MANAGEMENT LLC |
13F
|
Company |
0.34%
|
174,933
|
$2,162,172 | — | 31 Dec 2025 | |
| Ancora Advisors LLC |
13F
|
Company |
0.33%
|
170,469
|
$2,106,997 | — | 31 Dec 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.33%
|
168,643
|
$2,084,428 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for Emergent BioSolutions Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Sujata Tyagi Dayal | EBS | Common Stock | Sale | -12% | $115,610 | $8.40 | -13,761 | 100,563 | 01 May 2026 | Direct |
| Donald W. DeGolyer | EBS | Common Stock | Sale | -10.7% | $129,994 | $8.40 | -15,481 | 129,721 | 01 May 2026 | Direct |
| Kathryn C. Zoon | EBS | Common Stock | Sale | -17.7% | $144,453 | $8.40 | -17,202 | 79,941 | 01 May 2026 | Direct |
| Sujata Tyagi Dayal | EBS | Common Stock | Award | 28.5% | 25,344 | 114,324 | 30 Apr 2026 | Direct | ||
| Sujata Tyagi Dayal | EBS | Stock Option (Right to Buy) | Award | 11,296 | 11,296 | 30 Apr 2026 | Direct | |||
| Donald W. DeGolyer | EBS | Common Stock | Award | 21.2% | 25,344 | 145,202 | 30 Apr 2026 | Direct | ||
| Donald W. DeGolyer | EBS | Stock Option (Right to Buy) | Award | 11,296 | 11,296 | 30 Apr 2026 | Direct | |||
| Keith Katkin | EBS | Common Stock | Sale | -13.8% | $128,183 | $8.28 | -15,481 | 96,294 | 30 Apr 2026 | Direct |
| Keith Katkin | EBS | Common Stock | Award | 29.3% | 25,344 | 111,775 | 30 Apr 2026 | Direct | ||
| Keith Katkin | EBS | Stock Options (Right to Buy) | Award | 11,296 | 11,296 | 30 Apr 2026 | Direct | |||
| Marvin L. White | EBS | Common Stock | Award | 28.6% | 25,344 | 113,839 | 30 Apr 2026 | Direct | ||
| Marvin L. White | EBS | Stock Option (Right to Buy) | Award | 11,296 | 11,296 | 30 Apr 2026 | Direct | |||
| John D. Fowler Jr. | EBS | Common Stock | Award | 506.3% | 25,344 | 30,350 | 30 Apr 2026 | Direct | ||
| John D. Fowler Jr. | EBS | Stock Option (Right to Buy) | Award | 11,296 | 11,296 | 30 Apr 2026 | Direct | |||
| Ronald Richard | EBS | Common Stock | Award | 25.8% | 25,344 | 123,761 | 30 Apr 2026 | Direct | ||
| Ronald Richard | EBS | Stock Option (Right to Buy) | Award | 11,296 | 11,296 | 30 Apr 2026 | Direct | |||
| Kathryn C. Zoon | EBS | Common Stock | Award | 35.3% | 25,344 | 97,143 | 30 Apr 2026 | Direct | ||
| Kathryn C. Zoon | EBS | Stock Option (Right to Buy) | Award | 11,296 | 11,296 | 30 Apr 2026 | Direct | |||
| Neal Franklin Fowler | EBS | Common Stock | Award | 18.7% | 25,344 | 160,847 | 30 Apr 2026 | Direct | ||
| Neal Franklin Fowler | EBS | Stock Option (Right to Buy) | Award | 11,296 | 11,296 | 30 Apr 2026 | Direct | |||
| Zsolt Harsanyi | EBS | Common Stock | Award | 20.5% | 25,344 | 149,076 | 30 Apr 2026 | Direct | ||
| Zsolt Harsanyi | EBS | Stock Option (Right to Buy) | Award | 11,296 | 11,296 | 30 Apr 2026 | Direct | |||
| Paul Anthony Williams | EBS | Common Stock | Award | 159.7% | 100,111 | 162,792 | 29 Apr 2026 | Direct | ||
| Simon C. Lowry | EBS | Common Stock | Award | 128.7% | 100,111 | 177,914 | 29 Apr 2026 | Direct | ||
| Coleen Glessner | EBS | Common Stock | Award | 96.2% | 100,111 | 204,219 | 29 Apr 2026 | Direct | ||
| Richard S. Lindahl | EBS | Common Stock | Award | 75.5% | 162,680 | 378,047 | 29 Apr 2026 | Direct | ||
| Jessica Perl | EBS | Common Stock | Award | 170.9% | 104,282 | 165,286 | 29 Apr 2026 | Direct | ||
| William Hartzel | EBS | Common Stock | Award | 114.8% | 100,111 | 187,299 | 29 Apr 2026 | Direct | ||
| Joseph C. Papa | EBS | Common Stock | Award | 61.4% | 187,708 | 493,153 | 29 Apr 2026 | Direct | ||
| Paul Anthony Williams | EBS | Common Stock | Sale | -6% | $33,760 | $8.44 | -4,000 | 62,681 | 01 Apr 2026 | Direct |
| Joseph C. Papa | EBS | Common Stock | Tax liability | -10.8% | -37,055 | 305,445 | 05 Mar 2026 | Direct | ||
| Simon C. Lowry | EBS | Common Stock | Tax liability | -12% | -10,636 | 77,803 | 05 Mar 2026 | Direct | ||
| William Hartzel | EBS | Common Stock | Tax liability | -9.82% | -9,493 | 87,188 | 05 Mar 2026 | Direct | ||
| Jessica Perl | EBS | Common Stock | Tax liability | -9.58% | -6,465 | 61,004 | 05 Mar 2026 | Direct | ||
| Paul Anthony Williams | EBS | Common Stock | Tax liability | -12.4% | -9,397 | 66,681 | 05 Mar 2026 | Direct | ||
| Richard S. Lindahl | EBS | Common Stock | Tax liability | -9.89% | -23,650 | 215,367 | 05 Mar 2026 | Direct | ||
| Coleen Glessner | EBS | Common Stock | Tax liability | -7.3% | -8,199 | 104,108 | 05 Mar 2026 | Direct | ||
| Joseph C. Papa | EBS | Employee Stock Option (Right to buy) | Award | 16.5% | 252,194 | 1,784,694 | 03 Mar 2026 | Direct | ||
| John D. Fowler Jr. | EBS | Common Stock | Award | 5,006 | 5,006 | 03 Mar 2026 | Direct | |||
| Simon C. Lowry | EBS | Employee Stock Option (Right to buy) | Award | 43.5% | 44,834 | 147,833 | 03 Mar 2026 | Direct | ||
| William Hartzel | EBS | Employee Stock Option (Right to buy) | Award | 20.9% | 44,834 | 259,545 | 03 Mar 2026 | Direct | ||
| Jessica Perl | EBS | Employee Stock Option (Right to buy) | Award | 48.7% | 46,702 | 142,647 | 03 Mar 2026 | Direct | ||
| Paul Anthony Williams | EBS | Employee Stock Option (Right to buy) | Award | 21.3% | 44,834 | 254,948 | 03 Mar 2026 | Direct | ||
| Richard S. Lindahl | EBS | Employee Stock Option (Right to buy) | Award | 15% | 72,856 | 557,346 | 03 Mar 2026 | Direct | ||
| Coleen Glessner | EBS | Employee Stock Option (Right to buy) | Award | 18% | 44,834 | 294,447 | 03 Mar 2026 | Direct | ||
| Paul Anthony Williams | EBS | Common Stock | Tax liability | -0.15% | -116 | 76,078 | 01 Mar 2026 | Direct | ||
| Richard S. Lindahl | EBS | Common Stock | Tax liability | -0.28% | -683 | 239,017 | 01 Mar 2026 | Direct | ||
| Coleen Glessner | EBS | Common Stock | Tax liability | -0.28% | -313 | 112,307 | 01 Mar 2026 | Direct | ||
| Richard S. Lindahl | EBS | Employee Stock Option (Right to buy) | Expiration (or cancellation) of long derivative position with value received | -100% | -20,321 | 0 | 25 Feb 2026 | Direct | ||
| Jessica Perl | EBS | Common Stock | Tax liability | -1.34% | -918 | 67,469 | 09 Feb 2026 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.